Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...
The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.
LkldNow on MSN3d
Lakeland Resident Finds New Hope at Walk to End Alzheimer’sF or the last eight years, Lakeland resident Natalie Aviles has participated in Walk to End Alzheimer’s Polk County. Each year brings new motivation that, one day, her friends, ...
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...
"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...
Hosted on MSN5d
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming yearsToday, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...
Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...
A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback